Antibody Therapeutics for Life

Investor Updates

PharmAbcine, non-confidential slide deck Q3 2020
  • Written by PharmAbcine
  • Written date 2020-09-18 17:10:52
  • Inquire 611
Attachments PharmAbcine, non-confidential slide deck Q3 2020.pdf

PharmAbcine, non-confidential slide deck Q3 2020


Notice of Changes:

 

1.    The interim results of on-going phase Ib olinvacimab+pembrolizumab combo trials for mTNBC patients and rGBM patients in Australia have been added

 

2.    PMC-403’s data on the choroidal neovascularization mouse model have been added

3.    The two new preclinical settings in cooperation with


1) the National Institute of Allergy and Infectious Diseases(NIAID) to treat Systemic Capillary Leak Syndrome (SCLS, Clarkson Disease)


2) Wuxi Shuangliang Biotechnology (SLBio)
a Chinese biotech, to treat non-small cell lung cancer (NSCLC)

 

have been added.


 Other changes in layouts and designs have also been made.



Please check the attached file for details.



List





Prev PharmAbcine, non-confidential slide deck Q2 2020
Next PharmAbcine, Newsletter 3Q 2020